Home Featured Page 279

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

PT239 – Richie Ogulnick – Ibogaine, Unicity, and Beneficence

PsyBio Therapeutics Announces Application to List on OTCQX

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s...

Awakn launches Digital unit and signs agreement with the University of...

Psychedelic Bulletin: CA Decrim. Bill Passes Key Committee; MindMed Publishes MDMA...

COVID-19 and Psychedelic Group Work: It’s Still Too Soon

PTSF54 – Theft, Patents, and Ethical Psychedelic Companies

Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as...

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved...

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.